LEUKINE® (sargramostim) is the first and only FDA-approved GM-CSF1
GM-CSF=granulocyte-macrophage colony-stimulating factor.
The unique multipotent biology of LEUKINE stimulates multiple immune cell types1
LEUKINE efficacy has been demonstrated in a range of therapeutic settings for patients with hematologic malignancies1
Helpful links and downloadable resources are available
Contact PartnerTx for comprehensive information about LEUKINE, including resources that may help your patients with cost of treatment.
Complete the required fields below to connect with a LEUKINE specialist.
A donation will be made upon completion of the survey to support patients navigating the transplant journey.
Adverse events occurring in >10% of patients receiving LEUKINE in controlled clinical trials and reported in a higher frequency than placebo are:
LEUKINE is a leukocyte growth factor indicated for the following uses:
Please see full Prescribing Information for LEUKINE.
Adverse events occurring in >10% of patients receiving LEUKINE in controlled clinical trials and reported in a higher frequency than placebo are:
LEUKINE is a leukocyte growth factor indicated for the following uses:
Please see full Prescribing Information for LEUKINE.
Reference: 1. Leukine [package insert]. Boston, MA: Partner Therapeutics, Inc.; 2018.